Dermatol. praxi. 2017;11(4):178-181 | DOI: 10.36290/der.2017.043

The safety of secukinumab in treating psoriasis

doc. MUDr. Miloslav Salavec, CSc.
Klinika nemocí kožních a pohlavních Fakultní nemocnice Hradec Králové

Secukinumab shows a highly favourable safety profile, particularly in comparison with standard types of treatment, such asmethotrexate use, but also when compared with TNF-α blockers. The use of secukinumab is not accompanied by organ toxicity,serious infections, multiple sclerosis, reactivation of latent tuberculosis or hepatitis B, leukaemia/lymphoma, and non-melanomaskin cancers. The drug has been shown to have therapeutic effect as well as safety and can be accepted as standard in long-termpsoriasis treatment.

Keywords: psoriasis, biological therapy, secukinumab, safety

Received: August 27, 2019; Accepted: October 21, 2019; Prepublished online: October 21, 2019; Published: November 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Salavec M. The safety of secukinumab in treating psoriasis. Dermatol. praxi. 2017;11(4):178-181. doi: 10.36290/der.2017.043.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Blauvelt A, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol, 2015; 172(2): 484-493. Go to original source... Go to PubMed...
    2. SPC, Cosentyx 150 mg injekční roztok v předplněném peru, datum poslední revize textu 15. 8. 2017.
    3. van de Kerkhof PC, et al. Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol, 2016; 75(1): 83-98.e4. Go to original source... Go to PubMed...
    4. Bissonnette R, et al. Secukinumab Sustains Good Efficacy and Favourable Safety in Moderate to Severe Psoriasis up to 3 Years of Treatment: Results from A Double-Blind Extension Study. Br J Dermatol, 2017. Go to original source... Go to PubMed...
    5. Blauvelt A. Safety of secukinumab in the treatment of psoriasis. Expert Opin Drug Saf, 2016: 1-8. Go to original source... Go to PubMed...
    6. Cypowyj S, et al. Immunity to infection in IL-17-deficient mice and humans. Eur J Immunol, 2012; 42(9): 2246-2254. Go to original source... Go to PubMed...
    7. Hernandez-Santos N, Gaffen SL. Th17 cells in immunity to Candida albicans. Cell Host Microbe, 2012; 11(5): 425-435. Go to original source... Go to PubMed...
    8. Gaffen SL, Hernandez-Santos N, Peterson AC. IL-17 signaling in host defense against Candida albicans. Immunol Res, 2011; 50(2-3): 181-187. Go to original source... Go to PubMed...
    9. Reich K, Blauvelt A, Krueger J, et al. Candidiasis in Secukinumab-Treated Patients Is Non-serious and Transient: A Pooled Analysis of Data from 10 Phase 2 and 3 Clinical Trials in Psoriasis. Federation of Clinical Immunology Societes (FOCIS) Annual Meeting; 25-28 June 2014 Chicago Illinois USA: 2014 2014.
    10. Kammuller M, et al. Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections. Clin Transl Immunology, 2017; 6(8): e152. Go to original source... Go to PubMed...
    11. Schreiber SSBE, Deodhar A, Baeten D, Huang J, Gandhi K, Karyekar C, Fox T, Gaillez C. No increased incidence of inflammatory bowel disease among secukinumab-treated patients with moderate to severe psoriasis, psoriatic arthritis, or ankylosing spondylitis: data from 14 phase 2 and phase 3 clinical studies, poster OP 0113. EULAR 2016, 2016. poster OP 0113. Go to original source...
    12. Deodhar AASS, Gandhi K, Fox T, Gaillez CKCh. No Increased Risk of Inflammatory Bowel Disease Among Secukinumab-Treated Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis: Data from 14 Phase 2 and Phase 3 Clinical Studies. 2016 ACR/ARHP Annual Meeting, 2016. Abstract No. 962.
    13. Baeten D, Sieper J, Braun J, et al. Supplement Material (Protocol) to Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. New England Journal of Medicine. 2015; 373(26): 2534-2548. Go to original source... Go to PubMed...
    14. Blauvelt A, Prinz JC, Gottlieb AB, et al. Supplementary Appendix to Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015; 172(2): 484-493. Go to original source... Go to PubMed...
    15. Langley RG, Elewski BE, Lebwohl M, et al. Supplementary Material (Protocol) to Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials. N Engl J Med. Vol 371. 2014/07/10 ed2014: 326-338. Go to original source... Go to PubMed...

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.